Item 7.01 Regulation FD Disclosure
On February 26, 2020, Agile Therapeutics, Inc. (the "Company") updated its
corporate presentation that it intends to use at conferences and in meetings
with investors. The updates include information on the approval of its first
product, its plan for the commercialization of that product and recent financing
activities, including the net proceeds from its recent public offering of common
stock, which included the exercise in full by the underwriters of their option
to purchase additional shares of common stock. The aggregate net proceeds to
Agile Therapeutics from the offering were approximately $48.4 million, after
deducting underwriting discounts, commissions, and estimated offering expenses.
The Company is furnishing herewith a copy of the corporate presentation, which
is attached hereto as Exhibit 99.1.
In accordance with General Instructions B.2 and B.6 of Form 8-K, the information
included in this Item 7.01 (including Exhibit 99.1 attached hereto), shall not
be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference
into any filing made by the Company under the Exchange Act or the Securities
Act, except as shall be expressly set forth by specific reference in such a
filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number Description
99.1 Agile Therapeutics, Inc. Corporate Presentation dated February 26,
2020.
© Edgar Online, source Glimpses